Jun. 18 at 1:24 PM
$TELO shares pop 6%
$TELO on Wednesday announced new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation.
In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS.
The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling—a marker of mitochondrial dysfunction—under normal and stress-induced conditions.
$TELO $SPY $QQQ
